Atypicals no better than older meds in kids

Add yet another study to the mix of worries about atypical antipsychotic use in kids. Government research published today found that atypicals are no more effective than older antipsychotic drugs. But the newer meds are more expensive--and more likely to cause harmful side effects, the researchers said.

For instance, kids taking atypicals during the study gained weight quickly, putting on an average of nine to 13 pounds. Some gained 15 pounds in eight weeks, which as much as adults using the drugs gain over a year's time, the report said. These kids also developed cholesterol and insulin changes that are risk factors for diabetes. Those using an older antipsychotic drug gained less than a pound, on average, and showed little change in cholesterol and insulin levels.

Treatment guidelines should be revised to include some older drugs that had fallen out of favor, and thus fallen off the standard-usage list, the authors concluded.

Experts told the New York Times that the study results probably will change the treatment of 1 million children and teens with schizophrenia. That's bad news for the companies that make leading atypicals--Johnson & Johnson (Risperdal), Eli Lilly (Zyprexa), Bristol-Myers Squibb (Abilify), Pfizer (Geodon), and AstraZeneca (Seroquel). Prescription rates for these meds have enjoyed a strong growth curve, increasing more than fivefold among children over the past 15 years.

- see the UNC release
- read the NYT story

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Suggested Articles

Incyte and Novartis' Jakafi is eying a nod in chronic graft vs. host disease—and it may just have the data to get it done.

With a slate of vaccine authorizations on the horizon, vaccine execs from a trio of leading shot makers are looking at distribution hurdles ahead.

News of an FDA plant inspection for a Macrogenics drug boosted investor confidence in BMS' ability to meet its year-end deadline for liso-cel.